Immune reconstitution with two different rabbit polyclonal anti-thymocytes globulins

Area of Science:

• Transplantation immunology
• Immunosuppression therapy
• T cell biology

Background:

• Polyclonal anti-thymocyte globulins (ATG) are crucial for immunosuppression in transplantation.
• Thymoglobulin and Grafalon are two distinct ATG products with varying antibody profiles.
• Differences in ATG composition may lead to varied clinical outcomes.

Purpose of the Study:

• To compare lymphocyte reconstitution and clinical outcomes between kidney transplant patients treated with Grafalon versus Thymoglobulin.
• To investigate the impact of different ATG products on post-transplant immune profiles.

Main Methods:

• A nested study within a prospective multicentric kidney transplant cohort.
• 182 matched patients (91 per group) received either Thymoglobulin or Grafalon.
• Analysis of lymphocyte subsets, T cell activation, and senescence markers at one year post-transplant.

Main Results:

• Grafalon-treated patients showed significantly decreased recent thymic emigrants one year post-transplant.
• Thymoglobulin-treated patients exhibited increased T cell activation and senescence.
• No significant difference in acute rejection rates between the two ATG groups.
• Cytomegalovirus (CMV) disease was more frequent in the Thymoglobulin group.

Conclusions:

• Grafalon and Thymoglobulin demonstrate equivalent efficacy in preventing acute rejection in kidney transplant recipients.
• Thymoglobulin treatment is associated with a higher incidence of CMV disease.
• Significant differences in immune profiles exist one year post-transplant depending on the ATG product used.